Study Title

First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal Melanoma

Study Details

Description:

The primary aim of the study is to establish the maximum-tolerated dose (MTD) of 225Ac-MTI-201 in participants with metastatic uveal melanoma. The secondary aims are to describe the pharmacokinetics of 225Ac-MTI-201 and the toxic effects of 225Ac-MTI-201 in participants with metastatic uveal melanoma.

Sponsor:

Modulation Therapeutics, Inc.

Contacts:

Mark L McLaughlin, PhD

mlm@modulationtherapeutics.com

813-784-0033

Karen E Hayes, PhD

karenh@modulationtherapeutics.com

304-906-7692

Government Study Link:

NCT05496686 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468